Application of Proteomic Approaches to Accelerate Drug Development for Psychiatric Disorders.

Related Articles

Application of Proteomic Approaches to Accelerate Drug Development for Psychiatric Disorders.

Adv Exp Med Biol. 2017;974:69-84

Authors: Rahmoune H, Martins-de-Souza D, Guest PC

Abstract
Proteomic-based biomarkers are now an integral part of the drug development process. This chapter covers the role of proteomic biomarker tests as useful tools for improving preclinical research and clinical development. One medical area that has been lagging behind this process is the study of psychiatric disorders, and this is most likely due to the complexity of these diseases. The potential of incorporating biomarkers in the clinical pipeline to improve decision-making, accelerate drug development, improve translation and reduce development costs is also discussed, with a focus on psychiatric diseases like schizophrenia. This chapter will also discuss the next steps that must be taken to keep moving this process forwards.

PMID: 28353225 [PubMed - indexed for MEDLINE]

Log In